Descrizione del progetto
Nuovo screening per ridurre il rischio di cecità diabetica
A livello globale, la retinopatia diabetica è una delle principali cause di perdita della vista negli adulti di età compresa tra 20 e 74 anni. Circa il 25 % dei pazienti diabetici, pari a quasi 4 milioni di persone nell’UE, è affetto da una malattia dell’occhio diabetico. Poiché la prevalenza del diabete sta aumentando considerevolmente a causa sia delle tendenze demografiche sia dei cambiamenti nello stile di vita, anche la malattia dell’occhio diabetico aumenterà. La perdita della vista o la cecità potrebbero essere prevenute attraverso una diagnosi precoce. Il progetto aiVision, finanziato dall’UE, supporterà la diagnosi sviluppando un processo di esame medico di screening oculare migliorato agevolato da una piattaforma di telemedicina e utilizzerà algoritmi automatizzati, basati su un database di oltre 107 000 screening categorizzati del fondo oculare, per supportare il processo decisionale di diagnosi.
Obiettivo
AiVision is a unique telemedicine cloud platform powered by deep learning AI that supports the diagnosis of sight related diseases. It is created with the objective of optimizing the detection and treatment of a highly probable cause of blindness in diabetic patients, known as diabetic retinopathy.
Diabetic Retinopathy is the leading cause of blindness affecting the population that is less than 65 years old. After 15 years of significant improvements treating diabetes, 95% of type one diabetic patients and 60% of type 2 diabetic patients suffer from at least a mild and in some cases from severe diabetic retinopathy. In 2015, 415m people suffered from diabetes and this figure will grow up to 640m in 2040. There are 4,2M diabetics in the US, and around 24,000 new cases per year of advanced retinopathy due to diabetes.
AiVision intends to solve this health problem through an improved eye screening medical examination process facilitated by a telemedicine platform and automated algorithms that support diagnosis decision making.
We have gathered a database of more than 107,000 categorized eye fundus screenings which we have use in our algorithms, we have a partnership with the French Orthoptists Syndicate (with 1,000 professionals, it represents 90% of the sector) and are running our first paid pilots in France on 90 hospitals and health centres and working with the WHO in 4 African pilots.
There is a clear willingness to pay from the market actors: orthoptist and ophthalmologists consider that the increase in screened patients will vastly contribute to early detection of signs of retinopathy, allowing for better treatment.
AiVision is the core project of AiScreenings, a start-up founded in 2017 by partners with management, research, medical sciences and IT backgrounds. The company is based at the Polytechnique Institute business incubator (France). With a team of 9, we have generated our first 100.000€ of turnover in 2018 and received a 90.000€ innovation Grant.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
91120 PALAISEAU
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.